Freedland explores how enzalutamide’s role has expanded from advanced settings to earlier use in high-risk, biochemically recurrent prostate cancer. He discusses the clinical rationale for early initiation, particularly for urologists less familiar with systemic therapy, and compares enzalutamide with other androgen receptor pathway inhibitors in this population.
Rahul Aggarwal, MD, highlights final results from the phase 3 PRESTO trial in biochemically relapsed prostate cancer.
Qian Qin, MD, outlines the background and design of the phase 2 EXPLORE-RCC trial.
Petros Grivas, MD, PhD, highlights notable trial readouts across NMIBC, MIBC, and urothelial carcinoma.
Panelists discuss how understanding pharmacologic and mechanistic distinctions among androgen receptor pathway inhibitors helps clinicians tailor therapy selection and patient monitoring.
Panelists discuss how advances in systemic therapy have reshaped the treatment landscape for mCSPC, enabling more individualized and proactive first-line care.
Preliminary data from the study are promising.
The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure.
Panelists discuss how pairing IsoPSA with MRI strengthens risk assessment and supports more informed shared decision-making in prostate cancer care.
The segment reviews clinical trial outcomes and real-world findings on subcutaneous immunotherapy, focusing on efficacy, safety, and its practical application in daily urology practice.
Panelists discuss how IsoPSA strengthens diagnostic certainty by addressing gaps in MRI performance, offering a more reliable basis for biopsy decisions.
Pedro C. Barata, MD, MSc, FACP, outlines ARANOTE findings stratified by age subgroups.
Hear from 5 experts as they recap some of the top data from this year's ESMO Congress.
An expert discusses how he has integrated minimally invasive therapies into his practice workflow through a mutual evolution with his patients, noting that as these procedures became more amenable to office-based treatment, they lowered the bar for patient acceptance and allowed many who would have stayed on medications too long to undergo procedural intervention much earlier. The vast majority of his benign prostatic hyperplasia (BPH) work is now done in-office rather than in hospitals through advanced patient comfort techniques, including specialized lidocaine applications, bladder alkalinization with sodium bicarbonate, prostate nerve blocks, and nitrous oxide that allow about one-third of patients to fall asleep during procedures.
Panelists discuss how the promising approval of the gemcitabine intravesical system will likely drive future research into drug-device combinations for sustained drug delivery across various bladder cancer populations, including Bacillus Calmette-Guérin (BCG)-naive patients during shortages and muscle-invasive disease, potentially transforming localized bladder treatment approaches over the next decade.
Louise K. Kostos, MBBS, FRACP, PhD candidate, outlines initial findings from the phase 1/2 AlphaBet trial.
Beckermann explained that adenosine blockade may be better shown in the durability of response, so data collection in the study remains ongoing.
The findings revealed that patients prioritized improvements in overall survival and reductions in cancer recurrence at 5 years over all other treatment factors
Regarding the timing of sperm retrieval, the findings suggest it is reasonable and safe to delay the procedure until adulthood.
Chandler Park, MD, MSc, FACP, interviews urologist Neal D. Shore, MD, FACS, on the top updates in prostate cancer and bladder cancer at the 2025 European Society for Medical Oncology Congress.
Regarding feasibility, Helo highlighted that the asynchronous format is resource-efficient.
Panelists discuss how IsoPSA’s long-term predictive performance supports safer follow-up strategies and greater confidence in risk-based management.
This discussion compares subcutaneous and intravenous immunotherapy delivery, highlighting differences in clinical use, patient convenience, and overall treatment experience.
Panelists discuss how real-world evidence confirms IsoPSA’s predictive value, showing that high scores align with significantly greater long-term cancer risk.
Panelists discuss how practical implementation of the gemcitabine intravesical system requires integrating cystoscopic procedures into urology clinic workflows, training providers (including advanced practice providers) for device placement and removal, and developing effective patient counseling strategies for managing a 3-week indwelling device with proper tracking systems.
Scott Tagawa, MD, provides an overview of key findings from the PSMAddition study, evaluating 177Lu-PSMA-617 combined with ADT and ARPI in mHSPC.
Jeremie Calais, MD, PhD, shares key findings from the phase 2 LUNAR trial, assessing the safety and efficacy of adding 177Lu-PSMA therapy before SBRT in omHSPC.
An expert discusses how comparing the durability and treatment effects of newer minimally invasive therapies to gold standard transurethral resection of the prostate (TURP) or holmium laser enucleation depends heavily on surgeon skill. He notes that while an excellent TURP taken to the capsule or excellent holmium laser enucleation would generally be more durable and potentially lifelong, the reality is that surgical quality varies significantly between practices, making direct comparisons difficult as outcomes are largely surgeon dependent.
An expert discusses how the most common complications with minimally invasive benign prostatic hyperplasia (BPH) therapies are extremely mild (typically irritative voiding symptoms for a few days and some blood in urine) and how he counsels patients about trade-offs by explaining that every procedure has re-treatment and complication rates. He asks patients which “flavor of risk” they prefer while emphasizing that minimally invasive procedures “burn no bridges” and allow stepwise treatment progression because you can try something less invasive first and escalate later if needed.
